Lantheus Holdings, Inc. (LNTH)
USD 102.13
(0.13%)
USD 102.13
(0.13%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 326.66 Million USD | 1063.86% |
| 2022 | 28.06 Million USD | 139.38% |
| 2021 | -71.27 Million USD | -429.05% |
| 2020 | -13.47 Million USD | -142.55% |
| 2019 | 31.66 Million USD | -21.84% |
| 2018 | 40.51 Million USD | -67.16% |
| 2017 | 123.38 Million USD | 361.05% |
| 2016 | 26.76 Million USD | 281.49% |
| 2015 | -14.74 Million USD | -314.1% |
| 2014 | -3.56 Million USD | 94.21% |
| 2013 | -61.55 Million USD | -46.56% |
| 2012 | -42 Million USD | 69.4% |
| 2011 | -137.25 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 62.07 Million USD | -52.64% |
| 2024 Q1 | 131.06 Million USD | 26.78% |
| 2023 Q2 | 94.13 Million USD | 3453.44% |
| 2023 Q1 | -2.8 Million USD | 97.64% |
| 2023 FY | 326.66 Million USD | 1063.86% |
| 2023 Q4 | 103.38 Million USD | -21.66% |
| 2023 Q3 | 131.95 Million USD | 40.18% |
| 2022 Q4 | -119.18 Million USD | -294.64% |
| 2022 Q1 | 42.96 Million USD | 206.83% |
| 2022 Q2 | 43.05 Million USD | 0.22% |
| 2022 Q3 | 61.23 Million USD | 42.21% |
| 2022 FY | 28.06 Million USD | 139.38% |
| 2021 FY | -71.27 Million USD | -429.05% |
| 2021 Q1 | 9 Million USD | 364.01% |
| 2021 Q3 | -13.41 Million USD | 49.68% |
| 2021 Q4 | -40.21 Million USD | -199.78% |
| 2021 Q2 | -26.65 Million USD | -395.93% |
| 2020 Q4 | -3.41 Million USD | 46.57% |
| 2020 Q3 | -6.38 Million USD | 8.93% |
| 2020 FY | -13.47 Million USD | -142.55% |
| 2020 Q2 | -7.01 Million USD | -310.13% |
| 2020 Q1 | 3.33 Million USD | -68.07% |
| 2019 Q4 | 10.45 Million USD | 115.2% |
| 2019 Q1 | 9.94 Million USD | -25.16% |
| 2019 Q2 | 6.41 Million USD | -35.55% |
| 2019 FY | 31.66 Million USD | -21.84% |
| 2019 Q3 | 4.85 Million USD | -24.27% |
| 2018 Q2 | 9.74 Million USD | 18.68% |
| 2018 FY | 40.51 Million USD | -67.16% |
| 2018 Q1 | 8.21 Million USD | -91.55% |
| 2018 Q4 | 13.29 Million USD | 43.41% |
| 2018 Q3 | 9.26 Million USD | -4.88% |
| 2017 FY | 123.38 Million USD | 361.05% |
| 2017 Q3 | 8.52 Million USD | -37.29% |
| 2017 Q2 | 13.59 Million USD | 228.54% |
| 2017 Q1 | 4.13 Million USD | -15.01% |
| 2017 Q4 | 97.12 Million USD | 1039.17% |
| 2016 Q2 | 7.35 Million USD | -28.8% |
| 2016 FY | 26.76 Million USD | 281.49% |
| 2016 Q4 | 4.86 Million USD | 15.38% |
| 2016 Q1 | 10.32 Million USD | 163.61% |
| 2016 Q3 | 4.22 Million USD | -42.59% |
| 2015 Q2 | -24.42 Million USD | -6612.8% |
| 2015 Q1 | 375 Thousand USD | 65.2% |
| 2015 Q3 | 5.38 Million USD | 122.05% |
| 2015 FY | -14.74 Million USD | -314.1% |
| 2015 Q4 | 3.91 Million USD | -27.29% |
| 2014 Q2 | -1.63 Million USD | -27.32% |
| 2014 FY | -3.56 Million USD | 94.21% |
| 2014 Q4 | 227 Thousand USD | 126.18% |
| 2014 Q3 | -867 Thousand USD | 47.0% |
| 2014 Q1 | -1.28 Million USD | 89.55% |
| 2013 FY | -61.55 Million USD | -46.56% |
| 2013 Q1 | -19.81 Million USD | -107.46% |
| 2013 Q2 | -14.37 Million USD | 27.43% |
| 2013 Q3 | -15.06 Million USD | -4.78% |
| 2013 Q4 | -12.3 Million USD | 18.34% |
| 2012 FY | -42 Million USD | 69.4% |
| 2012 Q4 | -9.55 Million USD | 0.0% |
| 2011 FY | -137.25 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | -578.353% |
| Embecta Corp. | 70.4 Million USD | -364.007% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | -1639.502% |
| Dynavax Technologies Corporation | -6.38 Million USD | 5212.866% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 256.112% |
| Pacira BioSciences, Inc. | 41.95 Million USD | -678.598% |
| PainReform Ltd. | -9.34 Million USD | 3595.944% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 4250.712% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 7349.397% |
| SCYNEXIS, Inc. | 67.04 Million USD | -387.256% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 10642.444% |
| Cosmos Health Inc. | -18.54 Million USD | 1861.673% |
| Journey Medical Corporation | -3.85 Million USD | 8578.095% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 7349.397% |
| Safety Shot Inc | -15.08 Million USD | 2265.75% |
| Alpha Teknova, Inc. | -36.78 Million USD | 988.148% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 333.874% |
| Bright Green Corporation | -13.12 Million USD | 2588.344% |
| Procaps Group, S.A. | 42.54 Million USD | -667.891% |
| Theratechnologies Inc. | -23.95 Million USD | 1463.53% |
| Harrow Health, Inc. | -24.41 Million USD | 1438.171% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 6856.174% |
| Biofrontera Inc. | -20.13 Million USD | 1722.676% |
| DURECT Corporation | -27.62 Million USD | 1282.526% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -24722.264% |
| Cronos Group Inc. | -73.96 Million USD | 541.655% |
| OptiNose, Inc. | -35.48 Million USD | 1020.613% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 132.593% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 874.097% |
| RedHill Biopharma Ltd. | 23.91 Million USD | -1265.868% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -6505.885% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -206604.296% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 5302.172% |
| Radius Health, Inc. | -25.79 Million USD | 1366.57% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 5400.305% |
| ProPhase Labs, Inc. | -16.78 Million USD | 2046.496% |
| Phibro Animal Health Corporation | 2.41 Million USD | -13420.737% |
| Procaps Group S.A. | 42.54 Million USD | -667.891% |
| Alvotech | -551.73 Million USD | 159.207% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 3278.255% |
| Viatris Inc. | 54.7 Million USD | -497.186% |
| Rockwell Medical, Inc. | -8.43 Million USD | 3970.85% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 2161.733% |
| SIGA Technologies, Inc. | 68.06 Million USD | -379.898% |
| Tilray Brands, Inc. | -244.98 Million USD | 233.341% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -2619.229% |
| Shineco, Inc. | -22.44 Million USD | 1555.124% |
| PetIQ, Inc. | 2.13 Million USD | -15229.0% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 7693.523% |
| Incannex Healthcare Limited | -18.45 Million USD | 1869.657% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -30.821% |
| Alimera Sciences, Inc. | -20.13 Million USD | 1722.596% |
| Silver Spike Investment Corp. | 7.34 Million USD | -4350.357% |
| Assertio Holdings, Inc. | -331.94 Million USD | 198.409% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 5054.872% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 4101.635% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 1925.024% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 1728.639% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 303.812% |
| Hempacco Co., Inc. | -13.12 Million USD | 2588.641% |
| Talphera, Inc. | -18.39 Million USD | 1875.621% |
| Alvotech | -551.73 Million USD | 159.207% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | -816.506% |
| Currenc Group, Inc. | -15.3 Million USD | 2234.126% |
| Kamada Ltd. | 8.28 Million USD | -3843.276% |
| Indivior PLC | 2 Million USD | -16233.05% |
| Evoke Pharma, Inc. | -7.79 Million USD | 4292.103% |
| Flora Growth Corp. | -57.03 Million USD | 672.728% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 1728.639% |
| Evolus, Inc. | -61.68 Million USD | 629.563% |
| HUTCHMED (China) Limited | 100.78 Million USD | -224.133% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | -137.494% |
| Akanda Corp. | -32.27 Million USD | 1112.116% |